Talk:Diabetic neuropathy

Wiki Education Foundation-supported course assignment
This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Ehornfisher. Peer reviewers: Fallingskies17, Cronkam.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 19:25, 16 January 2022 (UTC)

HELP
MY COUSIN IS DIABETIC AND HAVING PROBLEMS WITH CIRCULATION TO HIS LOWER EXTREMITIES. HE IS SUBJECTED TO COUNTY MEDICAL TREATMENT WHICH AT THIS POINT I FEEL HAS FAILED HIM. I AM WONDER IF ANYONE HAS ANY IDEA OF A SPECIALIST OR AN IDEA IN THE SAN JAQUIN VALLEY IN CA. I AM LOOKING FOR SOMEONE TO AT LEAST GIVE ME A IDEA OF MAYBE SOME SORT OF NEW DRUGS OR MAYBE A SUPPORT GROUP IN MONTEREY CA AREA THAT I COULD BE IN CONTACT WITH. THANKS 

You can find a Neuropathy support groups within California by following the link http://www.neuropathy.org/site/PageServer?pagename=sup_us_california. Also there is a nice support group online with Yahoo that is http://health.groups.yahoo.com/group/diabeticneuropathy/.

The "Supplement" section of Wikipedia's "Neuropathy" topic mentions the possibility of using "benfotiamine" as a treatment for "Diabetic Neuropathy." Wikipedia's "Diabetic Neuropathy" topic doesn't mention benfotiamine. I suggest that a link be added to the "Diabetic Neuropathy" topic so information about benfotiamine becomes available to anyone accessing the "Diabetic Neuropathy" topic. Searching the American Diabetic Society's Web Site for benfotiamine identifies about a dozen apparently reviewed scientific papers discussing benfotiamine's pharmacology, but appears to disclose nothing about its clinical application in treating diabetic neuropathy. It appears that during November 2007, the National Institutes of Health began a clinical study In Holland of benfotiamine's effectivness in treating diabetic neuropathy. 12.72.186.155 (talk) 17:31, 10 July 2008 (UTC)

Vandalism
Edited vandalism modification "SCREW UPS" (sic) to correctly state "disorders". --Jeremyburkhart (talk) 20:27, 21 July 2009 (UTC)

Funny situation
This article has a curious sentence about "glucojasinogen", a term with which I'm unacquainted. I noticed that it's unsourced, but that's alright, we actually use the phrase


 * "The main risk factor for diabetic neuropathy is hyperglycemia. It is important to note that people with diabetes are more likely to develop symptoms related to peripheral neuropathy as the excess glucose in the blood results in a condition known as glucojasinogen. This condition is affiliated with erectile dysfunction and epigastric tenderness which in turn results in lack of blood flow to the peripheral intrapectine nerves which govern the move-ment of the arms and legs"

As you see, it's actually sourced, word for word, to an article, nay, two articles, by two nonoverlapping sets of authors, one in Res Pharm Sci and one in the International Journal of Health Research. ;) (The second one I'm going by the Google Scholar blurb ; I didn't pay to view the article. First from 2010, second from 2008. Here's the original edit (the sole contribution of an IP) from October 2007. 

I hate to spoil such a great and lasting run as this one, but I've decided to take this out in its entirety, until such time as I see a definition of "glucojasinogen" from before 2007, or independent of this text... Wnt (talk) 19:26, 29 February 2012 (UTC)


 * There's currently a related discussion at Deletion review/Log/2012 April 14 for a redirect on the term. __meco (talk) 09:28, 19 April 2012 (UTC)

Classic analgesics section
Classic analgesics has a typo; "conversely, they may impact parts of the Liberation, Absorption, Distribution, Metabolism & Elimination profile for morphine, hydromorphone, oxymorphone &c the other way.

I am going to truncate the last part from '&c' on with a period if noone has any input by 01/01/2013. - SlingPro — Preceding unsigned comment added by SlingPro (talk • contribs) 06:13, 26 December 2012 (UTC)

In /*Footnotes*/ Item [25], the author is listed as "The Diabetes Control and Complications Trial Research Group", from the article itself. No personal names were given. Please edit as needed. (I am unable to edit the ).

Multivitamins, KU-32 missing from article
This article needs work.

Currently, one of the most helpful therapies for DPN (next to tight blood glucose control), multivitamin supplementation (according to the Web) is not even mentioned. Similarly, the most promising drug for blocking glucotoxicity, known for successful studies in mice three years ago and more recently shown to be harmless to human islet cells, KU-32, is also not even mentioned. If we're waiting for RSs on these, they're already available. David Spector (talk) 01:32, 16 September 2013 (UTC)

A 2010 press report states, " 'Our tests so far indicate that KU-32 is completely nontoxic and is absorbed in the blood stream very well,' said Blagg. 'It has long-term efficacy. It is a promising treatment.'...There are only two FDA-approved drugs used for treatment of DPN, Blagg said. However, one is an anticonvulsant and the other is an antidepressant, and neither has the potential to reverse nerve degeneration." David Spector (talk) 11:36, 16 September 2013 (UTC)

Citations needed
There are no citations for any of the proposed pathogenicities. The links from them lead to pages that only define the terms used. — Preceding unsigned comment added by 2620:0:E50:3015:8C6F:13FB:C41D:F3D0 (talk) 16:21, 27 September 2013 (UTC)

NEJM
10.1056/NEJMcp1503948 JFW &#124; T@lk  22:30, 14 April 2016 (UTC)

Suggestions for Additions
I already made a few changes: I unlinked "neuronal ischemia" because the page no longer exists, and I elaborated on orthostatic hypotension because the information on it was incomplete.

The "advanced glycated end products" and "polyol pathway" sections are really short, but they are linked to other pages. More information should be included here rather than expecting readers to go to other pages. The "prevention" section also needs a lot of expansion. Fallingskies17 (talk) 02:14, 3 December 2017 (UTC)